Procurement and T-cell production Eligibility\*
\*a previously frozen, autologous leukapheresis product can be used for T-cell production Recipient Inclusion
* Age ≤21 years old
* Relapsed/refractory CD7+ AML
* Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR)
* Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy.
* Relapsed/refractory T-cell ALL/lymphoma
* Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR)
* Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy.
* Estimated life expectancy of \>12 weeks
* Karnofsky or Lansky (age-dependent) performance score ≥50
* Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
* Patient must have an identified HCT donor
* For females of childbearing age:
* Not lactating with intent to breastfeed
* Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
* For patients on Arm A: Meets eligibility criteria to undergo autologous apheresis, or have a previously frozen, autologous leukapheresis product that can be used for T-cell production
* For patients on Arm B: Have an available donor that meets donor criteria
Recipient Exclusion
* Known primary immunodeficiency
* Known HIV positivity
* Severe intercurrent bacterial, viral or fungal infection
* History of hypersensitivity to cornstarch or hydroxyethyl starch
* Patients with acute promyelocytic leukemia (APL)
* Known contraindication to protocol defined lymphodepleting chemotherapy regimens of Fludarabine/cyclophosphamide
* AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed.We define therapy failure as meeting one of the following
* contraindications to receiving targeted therapy; or
* toxicities that necessitate stopping the targeted therapy; or
* progressive disease
Donor eligibility criteria for Arm B of the study: Apheresis and manufacturing
* Recipient with relapsed CD7+ disease
* Allogeneic donor either previous transplant donor for recipient, or haplo-identical donor if previous transplant donor is not available or autologous collection is not feasible in patients that have not had a previous transplant
* HIV negative
* For females of child bearing age:
* Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND
o Not lactating with intent to breastfeed
* Regarding donation eligibility, is identified as either:
* Completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance; OR
* Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.
This will follow standard allogeneic donor criteria per FDA mandate as defined in our allogeneic transplant studies Recipient Pre-Treatment Tests Eligibility (Arm B) Inclusion
* Identified eligible study recipient with relapsed and/or refractory CD7-positive hematological malignancy Exclusion
* None
Treatment Eligibility (Arm A and Arm B) Inclusion
* Age ≤21 years old
* Detectable CD7+disease
* Estimated life expectancy of \>8 weeks
* Karnofsky or Lansky (age-dependent) performance score ≥ 50
* Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
* Patient must have an identified HCT donor
* Adequate cardiac function defined as left ventricular ejection fraction \>40%, or shortening fraction ≥25%
* EKG without evidence of clinically significant arrhythmia
* Adequate renal function defined as creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if \< 2 years of age)
* Adequate pulmonary function defined as forced vital capacity (FVC) ≥50% of predicted value; or pulse oximetry ≥92% on room air if patient is unable to perform pulmonary function testing
* Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
* For females of child bearing age:
* Not lactating with intent to breastfeed
* Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
* If sexually active, agreement to use birth control until 3 months after T-cell infusion. Male partners should use a condom.
* Available autologous transduced T-cells that has met GMP release criteria.
Exclusion
* Known primary immunodeficiency
* History of HIV infection
* Clinically significant active infection including fungal infection with ongoing antifungal therapy, viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6.
* Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD7-CAR T-cell infusion
* Receiving systemic immunosuppressive therapy in the 14 days prior to CD7-CAR T-cell infusion that in the opinion of PI will interfere with the infused product.
* Active CNS disease
* Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/ cyclophosphamide
* AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed agents). We define therapy failure as meeting one of the following:
* contraindications to receiving targeted therapy; or
* toxicities that necessitate stopping the targeted therapy; or
* progressive disease